BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38177295)

  • 1. Elevated expression of WSB2 degrades p53 and activates the IGFBP3-AKT-mTOR-dependent pathway to drive hepatocellular carcinoma.
    Li X; Zhang CC; Lin XT; Zhang J; Zhang YJ; Yu HQ; Liu ZY; Gong Y; Zhang LD; Xie CM
    Exp Mol Med; 2024 Feb; 56(1):177-191. PubMed ID: 38177295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma.
    Luo YD; Fang L; Yu HQ; Zhang J; Lin XT; Liu XY; Wu D; Li GX; Huang D; Zhang YJ; Chen S; Jiang Y; Shuai L; He Y; Zhang LD; Bie P; Xie CM
    J Hepatol; 2021 Jan; 74(1):96-108. PubMed ID: 32738450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated FBXL6 activates both wild-type KRAS and mutant KRAS
    Xiong HJ; Yu HQ; Zhang J; Fang L; Wu D; Lin XT; Xie CM
    Mil Med Res; 2023 Dec; 10(1):68. PubMed ID: 38124228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma.
    Pellegrino R; Calvisi DF; Neumann O; Kolluru V; Wesely J; Chen X; Wang C; Wuestefeld T; Ladu S; Elgohary N; Bermejo JL; Radlwimmer B; Zörnig M; Zender L; Dombrowski F; Evert M; Schirmacher P; Longerich T
    Hepatology; 2014 May; 59(5):1886-99. PubMed ID: 24285179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
    Grabinski N; Ewald F; Hofmann BT; Staufer K; Schumacher U; Nashan B; Jücker M
    Mol Cancer; 2012 Nov; 11():85. PubMed ID: 23167739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated FBXL6 expression in hepatocytes activates VRK2-transketolase-ROS-mTOR-mediated immune evasion and liver cancer metastasis in mice.
    Zhang J; Lin XT; Yu HQ; Fang L; Wu D; Luo YD; Zhang YJ; Xie CM
    Exp Mol Med; 2023 Oct; 55(10):2162-2176. PubMed ID: 37653031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
    Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
    Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
    Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
    Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [EEF1A2 inhibits the p53 function in hepatocellular carcinoma via PI3K/AKT/mTOR-dependent stabilization of MDM4].
    Longerich T
    Pathologe; 2014 Nov; 35 Suppl 2():177-84. PubMed ID: 25394965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway.
    Pu Z; Duda DG; Zhu Y; Pei S; Wang X; Huang Y; Yi P; Huang Z; Peng F; Hu X; Fan X
    J Transl Med; 2022 May; 20(1):212. PubMed ID: 35562734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway.
    Zhang M; Liu S; Chua MS; Li H; Luo D; Wang S; Zhang S; Han B; Sun C
    Cell Death Dis; 2019 Aug; 10(8):612. PubMed ID: 31406106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.
    Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB
    J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
    Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
    BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted inhibition of ACK1 can inhibit the proliferation of hepatocellular carcinoma cells through the PTEN/AKT/mTOR pathway.
    Wang B; Song K; Chen L; Su H; Gao L; Liu J; Huang A
    Cell Biochem Funct; 2020 Jul; 38(5):642-650. PubMed ID: 32162707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testis-specific protein, Y-linked 1 activates PI3K/AKT and RAS signaling pathways through suppressing IGFBP3 expression during tumor progression.
    Tu W; Yang B; Leng X; Pei X; Xu J; Liu M; Dong Q; Tao D; Lu Y; Liu Y; Yang Y
    Cancer Sci; 2019 May; 110(5):1573-1586. PubMed ID: 30815935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Notch1 signaling sensitizes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent DR5 expression.
    Wang C; Qi R; Li N; Wang Z; An H; Zhang Q; Yu Y; Cao X
    J Biol Chem; 2009 Jun; 284(24):16183-16190. PubMed ID: 19376776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway.
    Zhou C; Liu C; Liu W; Chen W; Yin Y; Li CW; Hsu JL; Sun J; Zhou Q; Li H; Hu B; Fu P; Atyah M; Ma Q; Xu Y; Dong Q; Hung MC; Ren N
    Theranostics; 2020; 10(10):4627-4643. PubMed ID: 32292519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KIFC3 regulates progression of hepatocellular carcinoma via EMT and the AKT/mTOR pathway.
    Lu S; Liu Y; Tian S; He Y; Dong W
    Exp Cell Res; 2023 May; 426(1):113564. PubMed ID: 36948354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gundelia tournefortii inhibits hepatocellular carcinoma progression by lowering gene expression of the cell cycle and hepatocyte proliferation in immunodeficient mice.
    Amer J; Salhab A; Jaradat N; Abdallah S; Aburas H; Hattab S; Ghanim M; Alqub M
    Biomed Pharmacother; 2022 Dec; 156():113885. PubMed ID: 36265306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long noncoding RNA PICSAR/miR-588/EIF6 axis regulates tumorigenesis of hepatocellular carcinoma by activating PI3K/AKT/mTOR signaling pathway.
    Liu Z; Mo H; Sun L; Wang L; Chen T; Yao B; Liu R; Niu Y; Tu K; Xu Q; Yang N
    Cancer Sci; 2020 Nov; 111(11):4118-4128. PubMed ID: 32860321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.